Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

HSP90β promotes osteoclastogenesis by dual-activation of cholesterol synthesis and NF-κB signaling

Cell Death & Differentiation (2022)Cite this article

Subjects

Abstract

Heat shock protein 90β (Hsp90β, encoded by Hsp90ab1 gene) is the most abundant proteins in the cells and contributes to variety of biological processes including metabolism, cell growth and neural functions. However, genetic evidences showing Hsp90β in vivo functions using tissue specific knockout mice are still lacking. Here, we showed that Hsp90β exerted paralogue-specific role in osteoclastogenesis. Using myeloid-specific Hsp90ab1 knockout mice, we provided the first genetic evidence showing the in vivo function of Hsp90β. Hsp90β binds to Ikkβ and reduces its ubiquitylation and proteasomal degradation, thus leading to activated NF-κB signaling. Meanwhile, Hsp90β increases cholesterol biosynthesis by activating Srebp2. Both pathways promote osteoclastogenic genes expression. Genetic deletion of Hsp90ab1 in osteoclast or pharmacological inhibition of Hsp90β alleviates bone loss in ovariectomy-induced mice. Therefore, Hsp90β is a promising druggable target for the treatment of osteoporosis.

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

Buy

All prices are NET prices.

Fig. 1: Hsp90β is upregulated during osteoclastogenesis.
Fig. 2: Osteoclast Hsp90ab1 deletion reduces osteoclastogenesis.
Fig. 3: Hsp90ab1 deletion improves ovariectomy-induced bone loss by inhibiting osteoclast activity.
Fig. 4: Osteoclast Hsp90ab1 deletion attenuates NF-κB signaling.
Fig. 5: Pathological up-regulation of Hsp90ab1 is transcriptionally regulated by c-Jun.
Fig. 6: Corylin inhibits RANKL-induced osteoclastogenesis and bone resorption in vitro.
Fig. 7: Corylin inhibits NF-κB activity.
Fig. 8: Corylin improves ovariectomy-induced bone loss.

Data availability

All data in this study are provided in the paper and Supplementary Materials. Additional data related to this study may be obtained from the authors.

References

  1. Soysa NS, Alles N. Osteoclast function and bone-resorbing activity: An overview. Biochem Bioph Res Co. 2016;476:115–20.

    Article  CAS  Google Scholar 

  2. Starling S. New anti-osteoporosis drug target identified. Nat Rev Endocrinol. 2021;17:5–5.

    Google Scholar 

  3. Wei HJ, Xu YH, Wang YB, Xu LT, Mo CY, Li LZ, et al. Identification of fibroblast activation protein as an osteogenic suppressor and anti-osteoporosis drug target. Cell Rep. 2020;33:108252.

  4. Tu KN, Lie JD, Wan CKV, Cameron M, Austel AG, Nguyen JK, et al. Osteoporosis: a review of treatment options. P T. 2018;43:92–104.

    PubMed  PubMed Central  Google Scholar 

  5. Ikebuchi Y, Aoki S, Honma M, Hayashi M, Sugamori Y, Khan M, et al. Coupling of bone resorption and formation by RANKL reverse signalling. Nature. 2018;561:195–200.

    Article  CAS  PubMed  Google Scholar 

  6. Karin M, Yamamoto Y, Wang QM. The IKKNF-kappa B system: A treasure trove for drug development. Nat Rev Drug Discov. 2004;3:17–26.

    Article  CAS  PubMed  Google Scholar 

  7. Clohisy JC, Yamanaka Y, Faccio R, Abu-Amer Y. Inhibition of IKK activation, through sequestering NEMO, blocks PMMA-induced osteoclastogenesis and calvarial inflammatory osteolysis. J Orthop Res. 2006;24:1358–65.

    Article  CAS  PubMed  Google Scholar 

  8. Boyce BF, Xing LP. Biology of RANK, RANKL, and osteoprotegerin. Arthritis Res Ther. 2007;9:S1.

  9. Luegmayr E, Glantschnig H, Wesolowski GA, Gentile MA, Fisher JE, Rodan GA, et al. Osteoclast formation, survival and morphology are highly dependent on exogenous cholesterol/lipoproteins. Cell Death Differ. 2004;11:S108–S118.

    Article  CAS  PubMed  Google Scholar 

  10. Sato T, Morita I, Murota S. Involvement of cholesterol in osteoclast-like cell formation via cellular fusion. Bone. 1998;23:135–40.

    Article  CAS  PubMed  Google Scholar 

  11. Grasser WA, Baumann AP, Petras SF, Harwood HJ Jr., Devalaraja R, Renkiewicz R, et al. Regulation of osteoclast differentiation by statins. J Musculoskelet Neuronal Interact. 2003;3:53–62.

    CAS  PubMed  Google Scholar 

  12. Ruan F, Zheng Q, Wang J. Mechanisms of bone anabolism regulated by statins. Biosci Rep. 2012;32:511–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Mundy G, Garrett R, Harris S, Chan J, Chen D, Rossini G, et al. Stimulation of bone formation in vitro and in rodents by statins. Science. 1999;286:1946–9.

    Article  CAS  PubMed  Google Scholar 

  14. Meier CR, Schlienger RG, Kraenzlin ME, Schlegel B, Jick H. HMG-CoA reductase inhibitors and the risk of fractures. JAMA. 2000;283:3205–10.

    Article  CAS  PubMed  Google Scholar 

  15. Inoue K, Imai Y. Fatostatin, an SREBP inhibitor, prevented RANKL-induced bone loss by suppression of osteoclast differentiation. Biochim Biophys Acta. 2015;1852:2432–41.

    Article  CAS  PubMed  Google Scholar 

  16. Inoue K, Imai Y. Identification of novel transcription factors in osteoclast differentiation using genome-wide analysis of open chromatin determined by DNase-seq. J Bone Min Res. 2014;29:1823–32.

    Article  CAS  Google Scholar 

  17. Jie Z, Xie Z, Xu W, Zhao X, Jin G, Sun X, et al. SREBP-2 aggravates breast cancer associated osteolysis by promoting osteoclastogenesis and breast cancer metastasis. Biochim Biophys Acta Mol Basis Dis. 2019;1865:115–25.

    Article  CAS  PubMed  Google Scholar 

  18. Zheng ZG, Zhang X, Zhou YP, Lu C, Thu PM, Qian C, et al. Anhydroicaritin, a SREBPs inhibitor, inhibits RANKL-induced osteoclastic differentiation and improves diabetic osteoporosis in STZ-induced mice. Eur J Pharm. 2017;809:156–62.

    Article  CAS  Google Scholar 

  19. Zheng ZG, Cheng HM, Zhou YP, Zhu ST, Thu PM, Li HJ, et al. Dual targeting of SREBP2 and ERRalpha by carnosic acid suppresses RANKL-mediated osteoclastogenesis and prevents ovariectomy-induced bone loss. Cell Death Differ. 2020;27:2048–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Seo YH. Organelle-specific Hsp90 inhibitors. Arch Pharm Res. 2015;38:1582–90.

    Article  CAS  PubMed  Google Scholar 

  21. Zheng ZG, Zhang X, Liu XX, Jin XX, Dai L, Cheng HM, et al. Inhibition of HSP90beta improves lipid disorders by promoting mature SREBPs Degradation via the Ubiquitin-proteasome System. Theranostics. 2019;9:5769–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Koga F, Xu W, Karpova TS, McNally JG, Baron R, Neckers L. Hsp90 inhibition transiently activates Src kinase and promotes Src-dependent Akt and Erk activation. Proc Natl Acad Sci USA. 2006;103:11318–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Yano A, Tsutsumi S, Soga S, Lee MJ, Trepel J, Osada H, et al. Inhibition of Hsp90 activates osteoclast c-Src signaling and promotes growth of prostate carcinoma cells in bone. Proc Natl Acad Sci USA. 2008;105:15541–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Price JT, Quinn JM, Sims NA, Vieusseux J, Waldeck K, Docherty SE, et al. The heat shock protein 90 inhibitor, 17-allylamino-17-demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line. Cancer Res. 2005;65:4929–38.

    Article  CAS  PubMed  Google Scholar 

  25. van der Kraan AG, Chai RC, Singh PP, Lang BJ, Xu J, Gillespie MT, et al. HSP90 inhibitors enhance differentiation and MITF (microphthalmia transcription factor) activity in osteoclast progenitors. Biochem J. 2013;451:235–44.

    Article  PubMed  Google Scholar 

  26. Lamoureux F, Thomas C, Yin MJ, Kuruma H, Fazli L, Gleave ME, et al. A novel HSP90 inhibitor delays castrate-resistant prostate cancer without altering serum PSA levels and inhibits osteoclastogenesis. Clin Cancer Res. 2011;17:2301–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Broemer M, Krappmann D, Scheidereit C. Requirement of Hsp90 activity for IkappaB kinase (IKK) biosynthesis and for constitutive and inducible IKK and NF-kappaB activation. Oncogene. 2004;23:5378–86.

    Article  CAS  PubMed  Google Scholar 

  28. Zhang S, Wang P, Hu B, Liu W, Lv X, Chen S, et al. HSP90 inhibitor 17-AAG attenuates nucleus pulposus inflammation and catabolism induced by M1-polarized macrophages. Front Cell Dev Biol. 2021;9:796974.

    Article  PubMed  Google Scholar 

  29. Thangjam GS, Dimitropoulou C, Joshi AD, Barabutis N, Shaw MC, Kovalenkov Y, et al. Novel mechanism of attenuation of LPS-induced NF-kappaB activation by the heat shock protein 90 inhibitor, 17-N-allylamino-17-demethoxygeldanamycin, in human lung microvascular endothelial cells. Am J Respir Cell Mol Biol. 2014;50:942–52.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Wei W, Zhou J, Chen L, Liu H, Zhang F, Li J, et al. Plasma levels of heat shock protein 90 alpha associated with colorectal cancer development. Front Mol Biosci. 2021;8:684836.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Fu R, Lv WC, Xu Y, Gong MY, Chen XJ, Jiang N, et al. Endothelial ZEB1 promotes angiogenesis-dependent bone formation and reverses osteoporosis. Nat Commun. 2020;11:460.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Kuo TR, Chen CH. Bone biomarker for the clinical assessment of osteoporosis: recent developments and future perspectives. Biomark Res. 2017;5:18.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Bouxsein ML, Boyd SK, Christiansen BA, Guldberg RE, Jepsen KJ, Muller R. Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J Bone Miner Res. 2010;25:1468–86.

    Article  PubMed  Google Scholar 

  34. Boyce BF, Xiu Y, Li J, Xing L, Yao Z. NF-kappaB-mediated regulation of osteoclastogenesis. Endocrinol Metab (Seoul). 2015;30:35–44.

    Article  CAS  Google Scholar 

  35. Vallabhapurapu S, Karin M. Regulation and function of NF-kappaB transcription factors in the immune system. Annu Rev Immunol. 2009;27:693–733.

    Article  CAS  PubMed  Google Scholar 

  36. Brown MS, Goldstein JL. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell. 1997;89:331–40.

    Article  CAS  PubMed  Google Scholar 

  37. Wei W, Schwaid AG, Wang XQ, Wang XD, Chen SL, Chu Q, et al. Ligand activation of ERR alpha by cholesterol mediates statin and bisphosphonate effects. Cell Metab. 2016;23:479–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Matys V, Kel-Margoulis OV, Fricke E, Liebich I, Land S, Barre-Dirrie A, et al. TRANSFAC and its module TRANSCompel: transcriptional gene regulation in eukaryotes. Nucleic Acids Res. 2006;34:D108–110.

    Article  CAS  PubMed  Google Scholar 

  39. Zhang X, Zhao W, Wang Y, Lu J, Chen X. The chemical constituents and bioactivities of psoralea corylifolia linn.: a review. Am J Chin Med. 2016;44:35–60.

    Article  PubMed  Google Scholar 

  40. Theoleyre S, Wittrant Y, Tat SK, Fortun Y, Redini F, Heymann D. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. Cytokine Growth Factor Rev. 2004;15:457–75.

    Article  CAS  PubMed  Google Scholar 

  41. Li LC, Varghese Z, Moorhead JF, Lee CT, Chen JB, Ruan XZ. Cross-talk between TLR4-MyD88-NF-kappaB and SCAP-SREBP2 pathways mediates macrophage foam cell formation. Am J Physiol Heart Circ Physiol. 2013;304:H874–84.

    Article  CAS  PubMed  Google Scholar 

  42. Cowen LE, Lindquist S. Hsp90 potentiates the rapid evolution of new traits: drug resistance in diverse fungi. Science. 2005;309:2185–9.

    Article  CAS  PubMed  Google Scholar 

  43. Miyata Y, Nakamoto H, Neckers L. The therapeutic target Hsp90 and cancer hallmarks. Curr Pharm Des. 2013;19:347–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Sha LZ, Wang XQ, Li J, Shi XZ, Wu LW, Shen Y, et al. Pharmacologic inhibition of Hsp90 to prevent GLT-1 degradation as an effective therapy for epilepsy. J Exp Med. 2017;214:547–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Kuan YC, Hashidume T, Shibata T, Uchida K, Shimizu M, Inoue J, et al. Heat shock protein 90 modulates lipid homeostasis by regulating the stability and function of sterol regulatory element-binding protein (SREBP) and SREBP cleavage-activating protein. J Biol Chem. 2017;292:3016–28.

    Article  CAS  PubMed  Google Scholar 

  46. Voss AK, Thomas T, Gruss P. Mice lacking HSP90beta fail to develop a placental labyrinth. Development. 2000;127:1–11.

    Article  CAS  PubMed  Google Scholar 

  47. Grad I, Cederroth CR, Walicki J, Grey C, Barluenga S, Winssinger N, et al. The molecular chaperone Hsp90 alpha is required for meiotic progression of spermatocytes beyond pachytene in the mouse. Plos One. 2010;5:e15770.

  48. Yu Z, Hong X, Zhang X, Zheng F, Liu F, Xu H, et al. Global proteomic analyses reveals abnormal immune regulation in patients with new onset ankylosing spondylitis. Front Immunol. 2022;13:838891.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Wang Q, Yao X, Ling Y, Huang Y, Chen C, Hou L, et al. Investigation of the mechanism of periploca forrestii against rheumatoid arthritis with network pharmacology-based analysis. Evid Based Complement Altern Med. 2022;2022:2993374.

    Google Scholar 

  50. Huang J, Huang J, Hu W, Zhang Z. Heat shock protein 90 alpha and 14-3-3eta in postmenopausal osteoporotic rats with varying levels of serum FSH. Climacteric. 2020;23:581–90.

    Article  CAS  PubMed  Google Scholar 

  51. Katiyar A, Kaur G, Rani L, Jena L, Singh H, Kumar L, et al. Genome-wide identification of potential biomarkers in multiple myeloma using meta-analysis of mRNA and miRNA expression data. Sci Rep. 2021;11:10957.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Rychkov D, Neely J, Oskotsky T, Yu S, Perlmutter N, Nititham J, et al. Cross-tissue transcriptomic analysis leveraging machine learning approaches identifies new biomarkers for rheumatoid arthritis. Front Immunol. 2021;12:638066.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Sun Y, Chen R, Zhu D, Shen ZQ, Zhao HB, Lee WH. Osteoking improves OP rat by enhancing HSP90beta expression. Int J Mol Med. 2020;45:1543–53.

    CAS  PubMed  PubMed Central  Google Scholar 

  54. Tran MT, Okusha Y, Feng Y, Sogawa C, Eguchi T, Kadowaki T, et al. A novel role of HSP90 in regulating osteoclastogenesis by abrogating Rab11b-driven transport. Biochim Biophys Acta Mol Cell Res. 2021;1868:119096.

    Article  CAS  PubMed  Google Scholar 

  55. Berghaus LJ, Moore JN, Hurley DJ, Vandenplas ML, Fortes BP, Wolfert MA, et al. Innate immune responses of primary murine macrophage-lineage cells and RAW 264.7 cells to ligands of Toll-like receptors 2, 3, and 4. Comp Immunol Microbiol Infect Dis. 2010;33:443–54.

    Article  PubMed  Google Scholar 

  56. MacDonald ML, Lamerdin J, Owens S, Keon BH, Bilter GK, Shang Z, et al. Identifying off-target effects and hidden phenotypes of drugs in human cells. Nat Chem Biol. 2006;2:329–37.

    Article  CAS  PubMed  Google Scholar 

  57. Jackson AL, Linsley PS. Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. Nat Rev Drug Disco. 2010;9:57–67.

    Article  CAS  Google Scholar 

  58. Angel P, Allegretto EA, Okino ST, Hattori K, Boyle WJ, Hunter T, et al. Oncogene jun encodes a sequence-specific trans-activator similar to AP-1. Nature. 1988;332:166–71.

    Article  CAS  PubMed  Google Scholar 

  59. David JP, Sabapathy K, Hoffmann O, Idarraga MH, Wagner EF. JNK1 modulates osteoclastogenesis through both c-Jun phosphorylation-dependent and -independent mechanisms. J Cell Sci. 2002;115:4317–25.

    Article  CAS  PubMed  Google Scholar 

  60. Takayanagi H, Kim S, Matsuo K, Suzuki H, Suzuki T, Sato K, et al. RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-beta. Nature. 2002;416:744–9.

    Article  CAS  PubMed  Google Scholar 

  61. Ikeda F, Nishimura R, Matsubara T, Tanaka S, Inoue J, Reddy SV, et al. Critical roles of c-Jun signaling in regulation of NFAT family and RANKL-regulated osteoclast differentiation. J Clin Invest. 2004;114:475–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We thank the State Key Laboratory of Natural Medicines, China Pharmaceutical University for providing experimental instruments. We thank Prof. Chaojun Li (Nanjing Medical University) for providing LysM-Cre mice.

Funding

This work was supported by National Key Research & Development Program of China for International S&T Cooperation Projects (2018YFE0117800), National Natural Science Foundation of China (81773957), CAMS Innovation Fund for Medical Sciences (2016-I2M-4-001), Beijing Outstanding Young Scientist Program (BJJWZYJH01201910023028), the Chinese Academy of Medical Sciences (CAMS) Central Public-interest Scientific Institution Basal Research Fund (2018RC350004, 2017PT31046).

Author information

Authors and Affiliations

  1. State Key Laboratory of Natural Medicines, China Pharmaceutical University, 210009, Nanjing, Jiangsu, China

    Hui-Min Cheng, Mingming Xing, Ya-Ping Zhou, Weitao Zhang, Zeyu Liu, Lan Li, Zuguo Zheng, Xiaoxuan Liu, Ping Li & Xiaojun Xu

  2. Department of Orthopedics, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, No.106, Zhongshan Second Road, Yuexiu District, Guangzhou, 510000, China

    Yuanchen Ma & Xiaojun Xu

  3. State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, China

    Pingping Li

  4. Diabetes Research Center of Chinese Academy of Medical Sciences, Beijing, 100050, China

    Pingping Li

Authors
  1. Hui-Min Cheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mingming Xing
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ya-Ping Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Weitao Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Zeyu Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Lan Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Zuguo Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yuanchen Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Pingping Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Xiaoxuan Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Ping Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Xiaojun Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

XX, H-MC, ZZ performed research design. H-MC, MX, Y-PZ performed animal experiment. H-MC, MX, WZ, ZL, LL acquired the data. H-MC, MX analyzed the data. XX, H-MC drafted and revised the manuscript. YM, PL, XL, PL provided technical and material support. All authors contributed to the preparation of the manuscript.

Corresponding author

Correspondence to Xiaojun Xu.

Ethics declarations

Competing interests

The authors declare no competing interests.

Ethics approval

All animal experiments were approved by the Laboratory Animal Management Committee of Jiangsu Province and the Institutional Animal Care and Use Committee of China Pharmaceutical University (Nanjing, China). This clinical study was approved by the Ethnic Committee of Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences) and the Affiliated Nanjing Hospital, Nanjing Medical University, and written informed consents were obtained from the patients before procedure [31].

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Edited by M Piacentini

Supplementary information

Rights and permissions

Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Cheng, HM., Xing, M., Zhou, YP. et al. HSP90β promotes osteoclastogenesis by dual-activation of cholesterol synthesis and NF-κB signaling. Cell Death Differ (2022). https://doi.org/10.1038/s41418-022-01071-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1038/s41418-022-01071-3

Search

Advanced search

Quick links